Biotime Inc., of Alameda, Calif., said the first patient was successfully treated in a pivotal trial in Europe assessing the efficacy of Renevia for the treatment of HIV-associated lipoatrophy, a disorder characterized by abnormal loss of body fat from under the skin that occurs in almost half of the approximately 3 million people on antiretroviral therapy in the U.S. and Europe.